Publication Date: 9 June 2020
Continuing Education Units: A maximum of 2.5 AMA PRA Category 1 CreditsTM

Course Description:

In this web-based program, physicians will learn how recent developments in sensor-based continuous glucose monitoring have advanced the management of Type 1 and Type 2 diabetes.

Course Objectives:

Upon completion of the proposed program activities, physicians will be able to:
  • Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for patients with T1D and T2D.
  • Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
  • Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
  • Educate patients with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in patients with T1d and T2D.
  • Identify which patients with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
  • Interpret and apply data and results from clinical trials and experts with experience in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T1D and T2D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
  • Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care setting; and understand the translational implications of deploying sensor-based, CGM-based technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.
  • Educate other clinical providers on the diabetes care team about the rationale, role, evidence, and outcome-enhancing results that are derived from employing technology-based CGM strategies—both patient- and physician-directed—across the broad spectrum of patients with diabetes.

Course Instructor Bio(s)

Headshot placeholder

James R. Gavin III, MD, PhD

Program Chair, Chief Medical Officer
Healing Our Village, Inc.
Clinical Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
Board Member/Advisory Panel: Abbott Diabetes Care; Janssen Pharmaceuticals; Merck; Novo Nordisk, Inc.; Intarcia Pharmaceuticals Consultant: Boehringer Ingelheim/Lilly Alliance; Janssen Pharmaceuticals Speaker’s Bureau: AstraZeneca; Boehringer Ingelheim/Lilly Alliance; Janssen Pharmaceuticals; Merck; Novo Nordisk, Inc.; Salix Pharmaceuticals
Headshot placeholder

Irl Hirsch, MD

Professor of Medicine, Diabetes Treatment and Teaching Chair
University of Washington Medical Center
Medical Director
UWMC Diabetes Care Center
Seattle, Washington, USA
Research: Medtronic Diabetes, Insulet
Consultant: Abbott Diabetes Care, Bigfoot, Roche
Headshot placeholder

Eden Miller, DO

Executive Director and Co-Founder
Diabetes Nation
High Lakes Health Care
St. Charles Hospital
Bend, Oregon, USA
Advisor or consultant: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals; Lilly; Novo Nordisk; Sanofi Aventis Speaker or Speakers Bureau: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lilly; Novo Nordisk
Headshot placeholder

Richard Bergenstal, MD

Executive Director
International Diabetes Center- Park Nicollet
Minneapolis, MN, United States
Clinical Research, Scientific Advisory Board, and/or Consultant: Abbott Diabetes Care, Ascenia, CeQur, Dexcom, Eli Lilly, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo, Roche, Sanofi, Senseonics and United Healthcare

attended a live program?




continuing medical education courses

Earn CME credits at no cost to you.